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 Abstract  
Oligopeptide transporters are abundantly expressed in various types of cancer cells. We here 
synthesized two novel dipeptides, L-Phenylalanylsarcosine (Phe-Sar) and 
4-(4-methoxyphenyl)-L-phenylalanyl sarcosine (Bip(OMe)-Sar), and examined their effect on 
the growth of human pancreatic cancer AsPC-1 cells, which are known to highly express 
oligopeptide transporter PEPT1/SLC15A1. Growth of AsPC-1 cells was inhibited by these 
two peptides and a typical PEPT1/SLC15A1 substrate Gly-Sar. Growth inhibition by Gly-Sar, 
Phe-Sar and Bip(OMe)-Sar was concentration-dependent with half-maximal inhibitory 
concentration of 50, 0.91 and 0.55 mM, respectively. These peptides also inhibited 
PEPT1-mediated [3H]Gly-Sar uptake with half-maximal inhibitory concentration of 2.6, 0.81 
and 0.27 mM, respectively. Thus, the rank order of the tumor cell growth inhibition by these 
three peptides was the same as that of PEPT1-inhibitory activity. Growth of AsPC-1 cells 
was also inhibited by 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid (BCH), which is a 
typical inhibitor of amino acid transporter system L. The growth inhibition by BCH and 
Gly-Sar was additive, suggesting that these compounds act at distinct loci. Oligopeptide 
transporters thus appear to be a promising target for inhibition of pancreatic cancer 
progression. These results also proposed the idea that oligopeptide transporter is required for 
growth of AsPC-1 cells.  
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 1. Introduction  
H+/oligopeptide cotransporter PEPT1/SLC15A1 is functionally expressed at plasma 
membranes of epithelial cells in small intestine and kidney in healthy mammals. It plays an 
important role in the absorption of peptides and peptide-mimetic drugs such as β-lactam 
antibiotics (Tsuji et al., 1987a; Tsuji et al., 1987b; Tsuji et al., 1987c; Nozawa et al., 2003; 
Mitsuoka et al., 2007; Kato et al., 2009), anti-herpesvirus drug valacyclovir (Balimane et al., 
1998; Han et al., 1998), the photosensitizer 5-aminolevulinic acid (Doring et al., 1998), and 
dipeptidyl derivatized L-Dopa, which is used to treat Parkinson's disease (Tsuji et al., 1990; 
Tamai et al., 1998; Tsuji, 1999). The other family member PEPT2 (encoded by SLC15A2) is 
predominantly expressed in epithelial cells, acting for reabsorption of dipeptides in the 
kidney (Rubio-Aliaga et al., 2003; Ocheltree et al., 2005; Frey et al., 2007; Shen et al., 2007) 
and efflux of the substrate drugs into cerebrospinal fluid in choroid plexus (Shen et al., 2003; 
Teuscher et al., 2004; Hu et al., 2007). PEPT1 and PEPT2 utilize an inwardly directed 
electrochemical proton gradient into cells to drive substrate transport.  
We have previously discovered oligopeptide transport activity in a cancer cell line, 
human fibrosarcoma HT1080, but not in the normal fibroblast cell line IMR-90 (Nakanishi et 
al., 1997). Subsequent studies have shown that other cancer cell lines also express 
oligopeptide transporters including PEPT1 (Gonzalez et al., 1998; Nakanishi et al., 2000; 
Knutter et al., 2002; Inoue et al., 2005). In addition, by utilizing tumor-specific transporter 
expression, as compared with limited expression in normal tissues, we have recently 
succeeded in detection of inoculated tumors with [11C]glycylsarcosine (Gly-Sar) as a positron 
emission tomography probe (Mitsuoka et al., 2008). Thus, [11C]Gly-Sar is a candidate 
tumor-imaging agent, and peptide transporters are considered to be a promising target for the 
delivery of such imaging agents. 
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 Interestingly, recent studies have revealed that tripeptides suppress tumor growth in 
vivo and in vitro (Jia et al., 2005; Lu et al., 2006; Yao et al., 2006; Shi et al., 2008). Although 
the molecular mechanism(s) responsible for the tumor suppression remains unknown, 
involvement of oligopeptide transporters seems likely, considering the broad expression 
profiles of PEPT1 and PEPT2 in various types of cancer cell lines (Mitsuoka et al., 2008), 
accepting di- and tripeptides as substrates (Biegel et al., 2006; Vig et al., 2006). It would be 
reasonable that di- and tripeptides are taken up as nutrients into cancer cells to support their 
high metabolic activity. However, little is known about the pathophysiological role of 
oligopeptide transporters in the tumors, and further studies are needed to clarify their roles in 
cancer cells.  
Accordingly, we hypothesized in the present study that inhibition of oligopeptide 
transporters in cancer cells would suppress the growth of the cells by reducing the supply of 
nutrients in vitro. As candidate inhibitors, we used synthetic dipeptides that were expected to 
show affinity for PEPT1 and PEPT2, but to be resistant to degradation by peptidases. Gly-Sar, 
a well characterized typical substrate of PEPTs (Ocheltree et al., 2005; Hu et al., 2008), 
contains a N-methyl amide isostere and is resistant to hydrolysis. Introduction of N-methyl 
amide bioisosteres as peptide bond replacements would thus confer peptidase resistance, 
while having a minimal effect on the affinity for PEPTs (Andersen et al., 2006; Knutter et al., 
2007). Hence we also used Phe-Sar and Bip(OMe)-Sar as candidate inhibitors. Among the 
various types of cancer cells expressing PEPT1 and/or PEPT2 (Mitsuoka et al., 2008), 
pancreatic cancer cell line AsPC-1 was selected to check growth inhibition potential of the 
synthetic dipeptides. Pancreatic cancer is one of the most common causes of cancer death. 
Due to its aggressive growth behavior with early local spread into the surrounding tissues, 
early metastasis, and resistance to radiation and most systemic therapies, the prognosis of 
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 pancreatic cancer remains poor. The efficacy of postoperative therapy (chemotherapy with or 
without chemoradiation therapy) in the management of this disease remains controversial 
(Neoptolemos et al., 2001; Neoptolemos et al., 2004), and new therapeutic strategies are 
necessary to combat this deadly disease. In the present study, we compared inhibition 
potential of three synthetic dipeptides for oligopeptide transport activity and cellular growth 
with an aim to examine whether the oligopeptide transporter is a promising target for cancer 
chemotherapy. 
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 2. Materials and Methods  
2.1. Chemicals and Cells  
[3H]Gly-Sar (18.5 GBq/mmol, Moravek Biochemicals Inc., Brea, CA) was obtained from 
Daiichi Pure Chemicals Co., Ltd. (Ibaraki, Japan). Inulin-carboxyl, [Carboxyl-14C] (161 
MBq/g) was from MP Biomedicals (CostaMesa, CA). All other reagents were of the highest 
grade available from Sigma-Aldrich (St. Louis, MO), Wako Pure Chemicals Industries, Ltd. 
(Osaka, Japan), Invitrogen Corporation (Carlsbad, CA), Kanto Chemicals (Tokyo, Japan) and 
Nacalai Tesque (Kyoto, Japan). 
2.2. Cell Culture  
AsPC-1 cells (CRL-1682; American Type Culture Collection) were cultured in RPMI 
medium (Invitrogen) containing 10% fetal bovine serum (Hyclone), 2 mM glutamine, 10 mM 
HEPES, 1 mM sodium pyruvate, and 1.5 g/l bicarbonate. HeLa cells stably expressing human 
PEPT1 (HeLa/PEPT1) or vector alone (HeLa/Mock) were previously established (Nakanishi 
et al., 2000) and cultured in MEM, Earle's salt (Invitrogen) containing 10% fetal bovine 
serum and 0.6 mg/ml geneticin. 
2.3. Synthesis of Bip(OMe)-Sar and Phe-Sar  
Bip(OMe)-Sar was synthesized from N-Boc-4-(4-methoxyphenyl)-L-phenylalanine (Sircar et 
al., 2002) and sarcosine benzyl ester. Phe-Sar was synthesized from N-Boc-L-phenylalanine 
and sarcosine benzyl ester. The synthetic routes are summarized in Fig. 1. Proton NMR 
spectra were recorded on a Varian INOVA600. δ values in parts per million relative to 
tetramethylsilane are given. Mass spectra were recorded with a Thermo Electron LCQ. 
4-(4-Methoxyphenyl)-L-phenylalanyl sarcosine (Bip(OMe)-Sar) was synthesized as follows. 
To a solution of N-Boc-4-(4-methoxyphenyl)phenylalanine (150 mg), sarcosine benzyl ester 
(76 mg), and 1-hydroxybenzotriazole (HOBt) (60 mg) in DMF (3 ml) was added ethyl 
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 N,N-dimethylaminopropyl carbodiimide monohydrochloride (WSCHCl) (85 mg) and the 
solution was stirred for 2 h. The solution was diluted with ethyl acetate, and then washed 
with water and brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography on silica gel with Et2O/hexane (1:1) to give 
N-Boc-4-(4-methoxyphenyl)-L-phenylalanyl sarcosine benzyl ester (152 mg). A mixture of 
the obtained benzyl ester (152 mg) and 10% Pd/C (15 mg) in methanol (7.5 ml) was stirred 
under an H2 atmosphere for 1 h. The mixture was filtered through Celite to remove the 
catalyst, and the filtrate was concentrated under reduced pressure to yield 
N-Boc-4-(4-methoxyphenyl)-L-phenylalanyl sarcosine (129 mg). The obtained Boc-protected 
dipeptide was dissolved in EtOAc (1 ml). To this solution, 4 N HCl/EtOAc (2 ml) was added 
and the mixture was stirred at room temperature for 1 h. The mixed solution was 
concentrated under reduced pressure, and the pH of the residue was adjusted to 8 with 
saturated aqueous NaHCO3. The mixed solution was purified by ODS column 
chromatography with MeCN/H2O (0:100 to 25:75). The eluate was concentrated in vacuo and 
lyophilized to give 4-(4-methoxyphenyl)-L-phenylalanyl sarcosine as an amorphous solid (83 
mg, 60% from N-Boc-4-methoxyphenyl-phenylalanine): 1H NMR (DMSO-d6) δ 2.81 (1H, 
d, J = 17.4), 2.88 (1H, dd, J = 13.2, 4.2), 3.13 (1H, dd, J = 13.2, 4.2), 3.53 (1H, d, J = 17.4), 
3.786 (3H, s), 3.790 (3H, s), 4.16 (1H, m), 7.00 (2H, m), 7.26 (2H, d, J = 7.8), 7.48 (2H, d, J 
= 7.8), 7.54-7.61 (2H, m); MS (ESI) m/z 343.1 (M+H)+. L-Phenylalanylsarcosine (Phe-Sar) 
was synthesized from N-Boc-L-phenylalanine and sarcosine benzyl ester using a procedure 
similar to that employed for the preparation of Bip(OMe)-Sar: 1H NMR (DMSO-d6) δ 2.60 
(1H, d, J = 17.6), 2.64 (3H, s), 2.85 (1H, dd, J = 13.6, 4.8), 3.11 (1H, dd, J = 13.6, 4.8), 4.15 
(1H, m), 7.09 (2H, m), 7.23-7.31 (3H, m), 8.26 (1H, s); MS (ESI) m/z 237.0 (M+H)+. 
2.4. Cellular Uptake Study  
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 Cells were seeded at a density of 5.0 × l04 (AsPC-1) or 2.0 × l04 (HeLa) cells per 96-well 
plate (Nalge Nunc) in growth media without antibiotics, and grown for 2 days. The passage 
numbers were in the ranges of 4 – 7 for AsPC-1 cells. Uptake of 2 µM [3H]Gly-Sar by the 
cultured cells was examined at 37 °C, pH 6.0 or 7.4 in Hanks' balanced salt solution. The 
procedures of the uptake experiments were described previously (Mitsuoka et al., 2007). In 
the inhibition study using unlabeled Gly-Sar or other dipeptides, the final concentration of 
[3H]Gly-Sar was set to be constant (2 µM) in the presence of various concentrations of 
unlabeled compound. The incubation mixture was prepared by mixing the stock solution 
containing [3H]Gly-Sar (4 µM) and those containing various concentration of unlabeled 
dipeptides at a ratio of 1 : 1 (v/v). Uptake of [3H]Gly-Sar was measured as the radioactivity 
associated with the cells using a liquid scintillation counter, LSC-6l00 (Aloka) and 
normalized by the control (without unlabeled dipeptide) value. The IC50 values 
(concentration at half-maximum inhibition of [3H]Gly-Sar uptake) for each unlabeled 
dipeptide were obtained using KaleidaGraph 4.0 (Synergy Software) by fitting the data to a 
four-parameter logistic:  
 Vmin +(Vmax- Vmin)/(1+(S/IC50)^n)   …Equation 1 
where Vmax, Vmin, S and n are the maximum uptake of [3H]Gly-Sar (without unlabeled 
dipeptide), the minimum uptake of [3H]Gly-Sar (in the presence of highest concentration of 
dipeptide), concentration of unlabeled dipepeide and the hill constant, respectively 
2.5. Membrane Potential Assay  
Measurements of membrane potential in HeLa/PEPT1 or HeLa/Mock cell lines were 
performed as previously described (Mitsuoka et al., 2009) using a FlexStation96 II (Nihon 
Molecular Devices). The EC50 values (concentration at half-maximum fluorescence response) 
were obtained using KaleidaGraph by fitting the data to a four-parameter logistic equation, 
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  y = (Flbase - Flmax) / [1 + (x / EC50)^S] + Flmax    …Equation 2 
 where Flbase, Flmax and S are baseline response, the maximum response and the slope, 
respectively. Because the maximum fluorescence values exhibited some day-to-day 
variability, all the fluorescence intensity data were normalized by the maximum value for 
Gly-Sar, which was routinely obtained in all experiments as a control. 
2.6. Evaluation of Cell Survival (CellTiterGlo ATP production assay) 
AsPC-1 cells (1 × 105 cells/100 µl/well) were plated in 96-well plates (Packard BioScience 
BV) and incubated at 37 °C under 95% air/5% CO2 for 4 h prior to drug addition to allow the 
cells to adhere to the bottom of the well. Cell survival was evaluated using CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega) according to the manufacturer's protocol with 
some modifications. The culture medium containing an appropriate concentration of test 
compound was replaced every day. Luminescence was measured by Wallac 1420 ARVO 
MX/Light (PerkinElmer Japan), and the intensity was expressed as the light counts per 
second (cps). The concentration required for 50% inhibition of growth (GI50) values were 
calculated using KaleidaGraph by nonlinear data fitting to the following equation 
 y = 100 × GI50 / (GI50 + x)                                      …Equation 3 
To evaluate the effect of osmolarity on the growth of AsPC-1 cells, D-mannitol (25, 50, and 
100 mM) was also included in the culture medium, and the cell survival was evaluated by the 
same method as described above.  
 
 
2.7. Statistical Analysis 
Results are presented as mean ± S.D. The statistical significance of differences between two 
means was determined by Student's t-test, and that of differences among means of more than 
two groups was determined by one-way analysis of variance followed by Dunnett's post hoc 
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 test using KaleidaGraph. Differences with a P-value of 0.05 or less were considered as 
statistically significant. 
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 3. Results  
3.1 Uptake of [3H]Gly-Sar in AsPC-1 Cells 
The uptake of [3H]Gly-Sar in AsPC-1 was measured in the absence or presence of unlabeled 
Gly-Sar (20 mM) (Fig. 2A). Uptake of [3H]Gly-Sar increased time-dependently. The uptake 
was notably reduced in the presence of unlabeled Gly-Sar. The uptake was found to be linear 
over the 20-min incubation period, and therefore, we evaluated initial uptake at 5 min in 
subsequent studies. The uptake of [3H]Gly-Sar in AsPC-l was significantly greater at acidic 
pH than that at neutral pH (Fig. 2B), as was the case for the transport by PEPTs.  
3.2. Modulation of Membrane Potential by Gly-Sar 
Modulation of membrane potential in HeLa/PEPT1 cells by addition of various 
concentrations of Gly-Sar was quantified. The membrane potential indicator dye yielded a 
time- and concentration-dependent increase of fluorescence intensity in response to Gly-Sar 
in HeLa/PEPT1 cells, reflecting membrane depolarization associated with proton-coupled 
substrate transport (Fig. 3A). There was no change in fluorescence intensity in HeLa/Mock 
cells after addition of Gly-Sar (data not shown). The change in fluorescence intensity from 
the base line was plotted against Gly-Sar concentration; the plots indicated saturable kinetics 
in HeLa/PEPT1 cells, but not in HeLa/Mock cells (Fig. 3B).  
3.3. Differences in Modulation of Membrane Potential by Synthetic Dipeptides 
Two additional synthetic dipeptides were also tested for the ability to activate PEPT1. In Fig. 
4A, PEPT1 activation is represented by the dose-dependent increase in fluorescence intensity 
caused by Gly-Sar and Phe-Sar; however, no activation was observed following the addition 
of Bip(OMe)-Sar, showing that Bip(OMe)-Sar was not transported by PEPT1. The EC50 and 
Flmax values obtained by nonlinear regression analysis are summarized in Table 1, and 
indicate that Phe-Sar has higher affinity than Gly-Sar for PEPT1.  
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 3.4. Effect of Synthetic Dipeptides on [3H]Gly-Sar Uptake  
The inhibitory effects of Gly-Sar, Phe-Sar and Bip(OMe)-Sar on PEPT1-mediated transport 
were studied in HeLa/PEPT1 cells using [3H]Gly-Sar as a typical substrate. In contrast to 
membrane potential studies, all the tested dipeptides inhibited the [3H]Gly-Sar uptake in 
HeLa/PEPT1 (Fig. 4B). The rank order of inhibitory potential was Bip(OMe)-Sar > Phe-Sar 
> Gly-Sar (Fig. 4B and Table 1). 
3.5 Inhibitory Effect of Synthetic Dipeptides on the Growth of AsPC-1 Cells 
To examine the cytotoxic and/or cytostatic effect of synthetic dipeptides, AsPC cells were 
cultured in the presence of each peptide, and the number of cells was quantified in terms of 
luminescence due to cellular ATP. Bip(OMe)-Sar and Gly-Sar suppressed growth of AsPC-1, 
and the inhibition occurred at lower concentration (1 mM) in the case of Bip(OMe)-Sar than 
Gly-Sar (100 mM) (Fig. 5). At the day 3, only 8.2% and 25.1% growth of the cells was 
achieved in the presence of Gly-Sar and Bip(OMe)-Sar, respectively. A synthetic leucine 
analogue, 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid (BCH) induced depletion of ATP, 
exhibiting a cytotoxic effect as reported previously (Nawashiro et al., 2006). When AsPC-1 
cells were cultured in medium containing both Gly-Sar and BCH, growth of the cells was 
further suppressed as compared with BCH alone (Table 2). Thus, the inhibitory effects of 
Gly-Sar and BCH appeared to be additive (Table 2). 
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 4. Discussion  
Oligopeptide transporters PEPT1 and PEPT2 are expressed in various types of human 
cancer cell lines, including pancreatic carcinoma (Gonzalez et al., 1998; Nakanishi et al., 
2000; Knutter et al., 2002; Inoue et al., 2005; Mitsuoka et al., 2008), and greater amount of 
peptide was reported to be accumulated in cancer cells compared with normal cells 
(Nakanishi et al., 1997); this would be consistent with function for nutrient uptake. This 
implies that a strategy of inhibition of PEPTs may result in decreased cellular growth of 
tumors. In the present study, we examined whether inhibition of PEPTs can suppress the in 
vitro growth of cancer cells using human pancreatic cancer cell line AsPC-1, which highly 
expresses PEPT1 (Gonzalez et al., 1998). These cells showed efficient uptake of a typical 
substrate, Gly-Sar, in a pH-dependent manner (Fig. 2). We found that the three dipeptides 
examined here inhibited both PEPT1-mediated transport (Fig. 4B) and growth of AsPC-1 
cells in a concentration-dependent manner (Fig. 5, Table 1). Thus, the present findings 
suggest that a strategy of inhibiting cancer cell growth by using inhibitors of PEPTs might be 
effective. 
Membrane potential assay revealed that Phe-Sar is a substrate of PEPT1 (Fig. 3). This 
assay is based on measurement of membrane depolarization resulting from the cotransport of 
protons and PEPT1 substrate (Faria et al., 2004; Vig et al., 2006). Plots of concentration 
dependency indicated that Phe-Sar has a lower EC50 value, and therefore, a higher affinity for 
PEPT1 than Gly-Sar (Table 1). On the other hand, Bip(OMe)-Sar inhibited [3H]Gly-Sar 
uptake (Fig. 4B) without modulating the membrane potential (Fig. 4A). Thus, Bip(OMe)-Sar 
is a non-transportable inhibitor of PEPT1. Bip(OMe)-Sar exhibited the lowest IC50 value, and 
is therefore the most potent inhibitor among the three dipeptides (Table 1). Because AsPC-1 
cells functionally express H+-dependent oligopeptide transport activity (Fig. 2), we also 
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 evaluated the effects of this compound on cell growth. AsPC-1 cells exhibited remarkable 
growth under normal culture conditions, whereas their growth was almost completely 
blocked in the presence of Bip(OMe)-Sar at 1 mM. The cell growth was also inhibited in the 
presence of Gly-Sar, but the growth inhibition by 1 mM Bip(OMe)-Sar was similar to that by 
100 mM Gly-Sar (Fig. 5). This is consistent with the much higher affinity (lower IC50) of 
Bip(OMe)-Sar than Gly-Sar for PEPT1 (Fig. 4 and Table 1). We confirmed that this growth 
inhibitory effect of the Gly-Sar on AsPC-1 cells was probably not due to high osmolarity of 
the culture medium added with Gly-Sar since addition of the equivalent molarity of 
D-mannitol showed no remarkable effect on the growth of the cells (data not shown). Because 
the rank order of GI50 values for AsPC-1 cells was Bip(OMe)-Sar > Phe-Sar > Gly-Sar, and 
the same rank order was also obtained for inhibition of PEPT1-mediated transport (IC50), it 
appears that inhibitory potential towards PEPT1 is important for the growth inhibition of 
AsPC-1 cells. However, the present findings cannot rule out the possibility that direct toxic 
effects of these dipeptides are also relevant to the growth inhibition of AsPC-1 cells. 
Therefore, further experiments are necessary to clarify the biological roles of PEPT1 in the 
growth of AsPC-1 cells. In addition, the GI50 value for Gly-Sar was about 50-fold higher than 
that for Phe-Sar, whereas the IC50 values for PEPT1 inhibition exhibited only three-times 
difference between Gly-Sar and Phe-Sar (Table 1), suggesting that the growth inhibition of 
AsPC-1 cells cannot be simply explained by the inhibition of PEPT1-mediated transport 
alone. 
In contrast to the dipeptides, BCH decreased the ATP content in AsPC-1 cells (Fig. 5), 
indicating the induction of cell death. BCH is a potent inhibitor for the system L amino acid 
transporter, which could be another molecular target for suppression of tumor growth 
(Nawashiro et al., 2006; Kim et al., 2008). The system L functions as an uptake transporter 
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 for nutrients, and inhibition of the transporter is expected to hinder cell growth. In the present 
study, cell growth was more potently suppressed by concomitant use of Gly-Sar and BCH, as 
compared with the use of Gly-Sar or BCH alone (Table 2). Such an additive effect may 
suggest that the compounds act at distinct loci, i.e., inhibition of oligopeptide transporter and 
system L may lead to distinct intracellular events. This would indicate that the combination 
of inhibition of the two transporters might be an effective approach for cancer chemotherapy.  
Cancer cell lines such as moderately differentiated pancreatic adenocarcinoma AsPC-1 
or poorly differentiated gastric cancer MKN45 can survive for longer than normal cells in the 
absence of essential nutrients such as amino acids and glucose (Izuishi et al., 2000). These 
two cell lines highly express oligopeptide transporter PEPT1 (Mitsuoka et al., 2008), which 
may act as an uptake mechanism for oligopeptides as alternative nutrients. In addition, when 
MKN45 cells were treated with a chemotherapeutic agent, 5-FU, gene expression of PEPT1 
and oligopeptide transport activity increased concomitantly with a decrease in the expression 
of facilitative glucose transporter and glucose uptake (Inoue et al., 2005). These observations 
suggest that the resistance of certain tumor cells to depletion of glucose or amino acids, or to 
chemotherapy, might be associated with enhanced metabolism of oligopeptides taken up via 
oligopeptide transporters. Pancreatic cancer is generally classed as a tumor that is highly 
resistant to chemotherapy. Nevertheless, our results indicate that inhibitors of oligopeptide 
transporter are promising candidates to suppress the growth of pancreatic cancer cells. In 
addition, it is likely that the inhibition of oligopeptide transporters in vivo would cause 
minimal side effects, because PEPT1 and PEPT2-deficient mice were found to be viable and 
fertile, and grew to normal size and weight without any obvious abnormalities (Shen et al., 
2003; Shen et al., 2007; Hu et al., 2008). Huang et al. (Huang et al., 2004) analyzed 
correlations between gene expression of transporters and chemosensitivity in 60 cancer cell 
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 lines established by the National Cancer Institute (NCI60) for drug screening. A positive 
correlation was observed between SLC15A1 expression and potency of some anticancer 
agents, including fluorodopan and teroxirone. This further supports the idea that inhibition 
and/or modulation of PEPT1 might be a promising approach for cancer chemotherapy. 
However, the growth inhibition of AsPC-1 cells by Bip(OMe)-Sar and Phe-Sar was observed 
at mM range in the present study (Table 1). In light of the concentrations at which growth 
inhibition effects are seen, it appears that much more potent inhibitors would be needed to 
apply the present findings in vitro to the clinical application in vivo. 
In conclusion, our results indicate that oligopeptide transporters are required to 
maintain AsPC-1 cell growth, and thus may be a suitable target for inhibition of human 
pancreatic cancer progression. 
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 Table 1 
Comparison of inhibition of PEPT1-mediated Gly-Sar uptake, membrane potential 
modulation, and growth inhibition of AsPC-1 cells by synthetic dipeptides 
 
Dipeptides IC50 (mM) a) EC50 (mM) b) GI50 (mM) c)
Gly-Sar 2.62 ± 1.99 0.608 ± 0.203 49.9 ± 19.3 
Phe-Sar 0.807 ± 0.174 0.263 ± 0.131 0.908 ± 0.758 
Bip(OMe)-Sar 0.274 ± 0.047 N/A 0.545 ± 0.163 
 
a) Half-maximal inhibitory concentration of dipeptides for PEPT1-mediated [3H]Gly-Sar 
uptake determined based on Equation 1. Mean ± calculated S.D. (n = 3) 
b) Half-maximal effective concentration of dipeptides for membrane potential change 
determined based on Equation 2. Mean ± S.D. (n = 9 and 4 for Gly-Sar and Phe-Sar, 
respectively). N/A, No activity  
c) Half-maximal inhibitory concentration of dipeptides for growth inhibition of AsPC-1 cells 
on day 3 determined based on Equation 3. Mean ± calculated S.D. (n = 3) 
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 Table 2 
Effect of the combination of inhibitors of oligopeptide and amino acid transporters on 
the growth of AsPC-1 cells a)
 
Inhibitors (mM) Growth (% of Control) b) P Value (vs. 
Control) 
P Value (vs. BCH)
Control 100 ± 20 − − 
Gly-Sar (25) 82.1 ± 22.1 0.179 0.020 
BCH (25) 43.4 ± 9.6 < 0.001 − 
Gly-Sar (25) + BCH (25) 28.8 ± 9.3 < 0.0001 0.043 
 
a) AsPC-1 cells (1 × 104 cells/well) were cultured for three days on a 96-well plate in the 
presence or absence of inhibitor(s) as indicated. 
b) The cell survival was quantified using CellTiter-Glo luminescent cell viability assay and 
normalized by the value in the absence of the inhibitor. Statistical significance was 
determined by ANOVA followed by Dunnett's post hoc test. Mean ± S.D., Control (n = 9); 
Gly-Sar (n = 4); BCH (n = 4); Gly-Sar + BCH (n = 6) 
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 Legends for Figures 
 
Figure 1 
Synthetic route for Bip(OMe)-Sar and Phe-Sar. 
 
Figure 2 
Time profile of [3H]Gly-Sar uptake in AsPC-1 (A) and effect of extracellular pH on the 
[3H]Gly-Sar uptake (B). 
(A) Cellular uptake of [3H]Gly-Sar (2 µM, 37 kBq/ml) in AsPC-1 cells was measured for 20 
min at pH 6.0 in the presence (open symbols) or absence (closed symbols) of 20 mM 
unlabeled Gly-Sar. (B) Cellular uptake of [3H]Gly-Sar in AsPC-1 cells were measured after 5 
min incubation at pH 6.0 or 7.4 in the presence (open columns) or absence (closed column) 
of 20 mM unlabeled Gly-Sar. Uptake of [3H]Gly-Sar was normalized by the medium 
concentration to give the distribution volume with dimensions of microliters per milligram of 
protein. An asterisk (*) indicates a significant difference from the control by Student's t-test 
(P < 0.05). Mean ± S.D. (n = 4). 
 
Figure 3 
Modulation of membrane potential by Gly-Sar in HeLa/PEPT1 cells. 
Membrane potential assay was performed using a fluorometric imaging plate reader, 
FlexStation II96, at pH 6.0. Gly-Sar (0 – 5000 µM) was added to HeLa/PEPT1 cells preloaded 
with membrane potential assay dye, and the fluorescence intensity was measured in real-time. 
In panel A, fluorescence intensity was plotted against time. In panel B, the data obtained at 
25 
 180 sec in HeLa/PEPT1 (closed symbols) and mock cells (open symbols) were plotted 
against Gly-Sar concentration in the medium. Mean ± S.D. (n = 3). 
 
Figure 4 
Effect of synthetic dipeptides on membrane potential (A) and [3H]Gly-Sar uptake (B) in 
HeLa/PEPT1 cells 
(A) Modulation of membrane potential by Gly-Sar (closed circles), Phe-Sar (open diamonds), 
and Bip(OMe)-Sar (open triangles) was quantified using a fluorometric imaging plate reader 
for 180 sec at pH 6.0. Peak fluorescence intensity corrected for basal fluorescence intensity 
was plotted against the compound concentration. All the data were normalized by the 
maximum value for Gly-Sar. Mean ± S.D. (n = 4). (B) Inhibitory effect of Gly-Sar (closed 
circles), Phe-Sar (open diamonds), and Bip(OMe)-Sar (open triangles) on the cellular uptake 
of [3H]Gly-Sar (2 µM, 37 kBq/ml) was measured for 5 min at pH 6.0. The PEPT1-mediated 
uptake was obtained by subtraction of the uptake by mock cells from that by HeLa/PEPT1 
cells and expressed as percentage of control value in the absence of inhibitors. Mean ± S.D. 
(n = 4).  
 
Figure 5 
Effect of synthetic dipeptides on the growth of AsPC-1 cells 
AsPC-1 cells (1 × 104 cells/well) were cultured on a 96-well plate in the presence of 100 mM 
Gly-Sar (closed circles), 1 mM Bip(OMe)-Sar (open triangles) or in their absence (open 
circles). After the designated days of culture, cell survival was evaluated using CellTiter-Glo 
luminescent cell viability assay and expressed as luminescence detected with ARVO 
MX/Light Wallac 1420 Multilabel Counter. The effect of 100 mM BCH, an inhibitor of 
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 amino acid transporters, was also evaluated (open squares). Statistical significance was 
determined by ANOVA followed by Dunnett's post hoc test. *; P < 0.05 vs. control (without 
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